SCHEMBL29338137

SCHEMBL29338137

CC(=O)COc1ccnc(Cl)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
PLAAT3 P53816 1/20 0.35
PLAAT5 Q96KN8 1/20 0.35
PLAAT2 Q9NWW9 1/20 0.35
PLAAT4 Q9UL19 1/20 0.35
KMT2A Q03164 2/20 0.35
FFAR1 O14842 1/20 0.35
NUDT1 P36639 1/20 0.34
MAPK8 P45983 1/20 0.34
MGMT P16455 1/20 0.34
TRPV1 Q8NER1 3/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
ALDH1A1 P00352 3/20 0.33
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33
MEN1 O00255 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27002851 0.81 SMN1; SMN2 (0.43) MTNR1AMTNR1BKMT2AALDH1A1MEN1
SCHEMBL20165978 0.80 KDM4E (0.54) KMT2ACA12ALDH1A1TSHRMEN1
SCHEMBL27850219 0.78 KDM4E (0.44) MTNR1AMTNR1BPLAAT3PLAAT5PLAAT2
SCHEMBL26116728 0.77 CYP1A2 (0.49) KMT2AALDH1A1CYP1A2MEN1SMN1; SMN2
SCHEMBL17117538 0.77 CASP3 (0.40) MTNR1AMTNR1BNUDT1
SCHEMBL31387127 0.77 CYP1A2 (0.49) KMT2AALDH1A1CYP1A2MEN1SMN1; SMN2
SCHEMBL2221308 0.75 KDM4E (0.40) KMT2ANUDT1MAPK8ALDH1A1SMN1; SMN2
SCHEMBL12798434 0.75 NUDT1 (0.38) PLAAT3PLAAT5PLAAT2PLAAT4FFAR1
SCHEMBL7229458 0.73 MAPT (0.41) MTNR1AMTNR1BPLAAT3PLAAT5PLAAT2
SCHEMBL11369551 0.72 MGMT (0.36) KMT2AMAPK8MGMTCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor LIFEARC (GB) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor DCK, ERCC2, POLK MTNR1A 3226/4885MTNR1B 2971/4885PLAAT3 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.